<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389259</url>
  </required_header>
  <id_info>
    <org_study_id>70/04*1</org_study_id>
    <nct_id>NCT00389259</nct_id>
  </id_info>
  <brief_title>Scopolamine Treatment for Patients With Organophosphate Poisoning</brief_title>
  <official_title>Scopolamine Treatment for Patients With Organophosphate Poisoning - a Randomized, Double Blind, Placebo-Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israeli MOH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Diabetes Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist&#xD;
      act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a&#xD;
      common cause of death among people who commit suicide in developing countries. OPs poisoning&#xD;
      also frequently occurs after accidental exposure to agricultural OPs and in children as a&#xD;
      result of unintentional ingestion.&#xD;
&#xD;
      The use of competitive inhibitors of acetylcholine other than atropine for patient with&#xD;
      organophosphate (OP) poisoning is controversial. Because scopolamines' ability to cross the&#xD;
      blood brain barrier is better than atropine, it has been suggested that scopolamine should be&#xD;
      used OP poisoned patients who have central nervous system (CNS) manifestations. However there&#xD;
      is controversy regarding its potential benefit in the treatment of organophosphate poisoning&#xD;
      in humans. To the best of our knowledge there are no randomised controlled studies on the use&#xD;
      of scopolamine in humans. This prospective randomised controlled study is aimed to determine&#xD;
      whether adding scopolamine to the standard treatment of atropine and oximes in patients with&#xD;
      CNS symptoms of OP poisoning improve the outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: to determine whether adding scopolamine to the standard treatment of atropine and&#xD;
      oximes improve the outcome of patients with OP poisoning and CNS manifestations. Design: A&#xD;
      multi-center, randomized, double blind, placebo controlled study. Setting: Emergency&#xD;
      Departments &amp; Intensive Care Units in Israel. Participants: Patients 2 -60 years old with&#xD;
      acute OP poisoning and CNS manifestations. Interventions: In addition to standard treatment&#xD;
      with atropine and obidoxime, eligible patients will be randomly assigned to one of two&#xD;
      treatment groups, scopolamine group, and placebo group (both given in the same volume).&#xD;
      Scopolamine will be given IM or IV in a dose of 0.25mg for adults and 0.006mg/kg for children&#xD;
      every 4 hours. At least three doses of scopolamine (or placebo) will be given. The medical&#xD;
      staff will be blinded to the treatment given. Main outcome measures: Improvement in&#xD;
      neurological status, duration of seizures and number of days on ventilator. Data analysis:&#xD;
      The main outcome measures, will be compared using the Student's t-test or the Mann-Whitney&#xD;
      tests as appropriate. The *2 or Fisher Exact tests, as appropriate, will be used for&#xD;
      comparisons of categorical variables. We will use multiple logistic regression to examine the&#xD;
      extent to which variables predict success or failure of the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in neurological status as measured by the Glasgow Coma Scale</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of seizures.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of days on ventilator</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cumulative dose of atropine</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for benzodiazepines</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the ICU</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects and complications</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment at discharge</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment 3 month after the exposure</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuro-cognitive assessment at 3 month</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to discharge</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in hospital</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neurotoxicity Syndromes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Look alike drug Q 4h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV placebo q4h</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 2- 60 years&#xD;
&#xD;
          -  At least two of the following three criteria:&#xD;
&#xD;
               -  Known exposure to an organophosphate or carbamate insecticide in the last 72&#xD;
                  hours.&#xD;
&#xD;
               -  Symptoms and signs typical to organophosphate poisoning involving at least two&#xD;
                  systems (gastrointestinal, respiratory, skin, eyes,) See appendix&#xD;
&#xD;
               -  Low levels of plasma butyrylcholinesterase (less than 50% of the lower normal&#xD;
                  range )&#xD;
&#xD;
          -  CNS involvement in the first 72 hours after exposure: determined by finding at least&#xD;
             one of the following major criteria or at least two of the minor criteria&#xD;
&#xD;
        Major criteria for CNS involvement:&#xD;
&#xD;
          -  Seizures&#xD;
&#xD;
          -  Extrapyramidal or Parkinson like symptoms&#xD;
&#xD;
          -  Decreased level of consciousness (GCS&lt; 12)&#xD;
&#xD;
        Minor criteria for CNS involvement:&#xD;
&#xD;
          -  GCS 14-12&#xD;
&#xD;
          -  Confusion&#xD;
&#xD;
          -  Hallucinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to scopolamine&#xD;
&#xD;
          -  Glaucoma, narrow-angle (angle-closure)&#xD;
&#xD;
          -  Tachyarrhythmias, congestive heart failure&#xD;
&#xD;
          -  Obstructive gastrointestinal disease&#xD;
&#xD;
          -  Myasthenia Gravis&#xD;
&#xD;
          -  Reflux esophagitis&#xD;
&#xD;
          -  Ulcerative colitis&#xD;
&#xD;
          -  Known obstructive uropathy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient or legal guardian unable to give informed consent (see comment under ethics)&#xD;
&#xD;
          -  Severe co-morbidity (multi-trauma, advanced cancer, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Kozer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Hospital</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <keyword>Insecticides</keyword>
  <keyword>Organophosphate</keyword>
  <keyword>Scopolamine</keyword>
  <keyword>randomized control study</keyword>
  <keyword>Organophosphate or carbamate intoxication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Poisoning</mesh_term>
    <mesh_term>Organophosphate Poisoning</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

